EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Turnstone Biologics's Enterprise Value is $-8.75 Mil.
Turnstone Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-66.96 Mil. Therefore, Turnstone Biologics's EV-to-FCF for today is 0.13.
The historical rank and industry rank for Turnstone Biologics's EV-to-FCF or its related term are showing as below:
TSBX'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.31 Med: 0.44 Max: 1.02
Current: 0.2
During the past 3 years, the highest EV-to-FCF of Turnstone Biologics was 1.02. The lowest was -3.31. And the median was 0.44.
TSBX's EV-to-FCF is ranked better than 87.34% of 379
companies
in the Biotechnology industry
Industry Median: 8.34
vs TSBX: 0.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Turnstone Biologics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Turnstone Biologics's EV-to-FCF
For the Biotechnology subindustry, Turnstone Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turnstone Biologics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Turnstone Biologics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Turnstone Biologics's EV-to-FCF falls into.
Turnstone Biologics's current Enterprise Value is $-8.75 Mil.
Turnstone Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Turnstone Biologics's PE Ratio for today is calculated as:
Turnstone Biologics's share price for today is $2.90.
Turnstone Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.549.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Turnstone Biologics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Turnstone Biologics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Turnstone Biologics (Turnstone Biologics) Business Description
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSBX has been successfully added to your 